Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II 6-mercaptopurine + low-dose methotrexate in BRCA-mutated breast and ovarian cancers
2009-016846-16Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mercaptopurine and methotrexate in breast cancer, ovarian cancer, fallopian tube cancer (PFTC) and 1 more, sponsored by University of Oxford. Primary endpoint: Objective response rate at 8 weeks. Started Nov 2010; status: completed.
02
Drugs
mercaptopurinemethotrexate
03
Conditions
breast cancerovarian cancerfallopian tube cancer (PFTC)serous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on 2009-016846-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016846-16.